Cambridge Investment Research Advisors
NGM

Cambridge Investment Research Advisors’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Cambridge Investment Research Advisors’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-8,306
Closed -$241K – 3183
2021
Q1 		$241K Hold
8,306
– – ﹤0.01% 2459
2020
Q4 		$252K Buy
+8,306
New +$182K ﹤0.01% 2283

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GA
Greenspring Associates Owings Mills, Maryland $1.48B AUM 61.93% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Cambridge Investment Research Advisors's NGM Position: Q2 2021 in Review

Cambridge Investment Research Advisors sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2021, closing a stake of 8,306 shares — an estimated $241K sold.

Cambridge Investment Research Advisors first reported a position in NGM in Q4 2020 and held it in 2 quarters. The position peaked at $252K in Q4 2020. 107 funds tracked by Wall St. Rank hold NGM as of Q2 2021.

  • Cambridge Investment Research Advisors reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 8,306 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2021, an estimated $241K.
  • Cambridge Investment Research Advisors first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q4 2020 and held it in 2 quarters.
  • Cambridge Investment Research Advisors's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $252K in Q4 2020.
  • 107 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2021.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2021, filed 10 Aug 2021.